“Effects of galcanezumab on acute medication use and health care resource utilization in treatment-resistant migraine: results from randomized, double blind, placebo-controlled clinical trial, conquer” (2020) Headache Medicine, 11(Supplement), p. 27. doi:10.48208/HeadacheMed.2020.Supplement.27.